Related references
Note: Only part of the references are listed.Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Amanda Katherina Herbrand et al.
JAMA NETWORK OPEN (2021)
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016
Aviv Ladanie et al.
JAMA NETWORK OPEN (2020)
The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting
Marta Herrero Fernandez et al.
FRONTIERS IN PHARMACOLOGY (2019)
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Amanda Katherina Herbrand et al.
ESMO OPEN (2019)
State insurance mandates and off-label use of chemotherapy
Fabrice Smieliauskas et al.
HEALTH ECONOMICS (2018)
Off-label drug use in oncology: a systematic review of literature
M. M. Saiyed et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With NewCancer Medicines
Sebastian Salas-Vega et al.
JAMA ONCOLOGY (2017)
Cross-comparison of cancer drug approvals at three international regulatory agencies
N. Samuel et al.
CURRENT ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement
Eric I. Benchimol et al.
PLOS MEDICINE (2015)
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
M. Joerger et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists
Rena M. Conti et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
LANCET (2007)
Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer
Donald C. McMillan et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2007)
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study
S Choquet et al.
BLOOD (2006)
Share Paper
